Rosuvastatin, C-reactive protein, LDL cholesterol, and the JUPITER trial

Lancet. 2009 Jul 4;374(9683):24; author reply 26-7. doi: 10.1016/S0140-6736(09)61227-7.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Biomarkers / metabolism
  • C-Reactive Protein / drug effects
  • C-Reactive Protein / genetics
  • C-Reactive Protein / metabolism*
  • Cardiovascular Diseases / etiology
  • Cardiovascular Diseases / metabolism
  • Cardiovascular Diseases / prevention & control*
  • Causality
  • Cholesterol, LDL / blood*
  • Cholesterol, LDL / drug effects
  • Confounding Factors, Epidemiologic
  • Fluorobenzenes / therapeutic use*
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use*
  • Patient Selection
  • Polymorphism, Genetic / genetics
  • Pyrimidines / therapeutic use*
  • Research Design
  • Rosuvastatin Calcium
  • Sulfonamides / therapeutic use*

Substances

  • Biomarkers
  • Cholesterol, LDL
  • Fluorobenzenes
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Pyrimidines
  • Sulfonamides
  • Rosuvastatin Calcium
  • C-Reactive Protein